Changes in NAD/ADP-ribose metabolism in rectal cancer

Abstract

The extent of ADP-ribosylation in rectal cancer was compared to that of the corresponding normal rectal tissue. Twenty rectal tissue fragments were collected during surgery from patients diagnosed as having rectal cancer on the basis of pathology results. The levels of ADP-ribosylation in rectum cancer tissue samples (95.9 ± 22.1 nmol/ml) was significantly higher than in normal tissues (11.4 ± 4 nmol/ml). The level of NAD+ glycohydrolase and ADP-ribosyl cyclase activities in rectal cancer and normal tissue samples were measured. Cancer tissues had significantly higher NAD+ glycohydrolase and ADP-ribosyl cyclase activities than the control tissues (43.3 ± 9.1 vs 29.2 ± 5.2 and 6.2 ± 1.6 vs 1.6 ± 0.4 nmol min⁻¹ mg⁻¹). Approximately 75% of the NAD+ concentration was consumed as substrate in rectal cancer, with changes in NAD+/ADP-ribose metabolism being observed. When [14C]-ADP-ribosylated tissue samples were subjected to SDS-PAGE, autoradiographic analysis revealed that several proteins were ADP-ribosylated in rectum tissue. Notably, the radiolabeling of a 113-kDa protein was remarkably greater than that in control tissues. Poly(ADP)-ribosylation of the 113-kDa protein in rectum cancer tissues might be enhanced with its proliferative activity, and poly(ADP)-ribosylation of the same protein in rectum cancer patients might be an indicator of tumor diagnosis.

Introduction

Different lines of evidence indicate that cellular NAD+ content influences cellular responses to genomic damage by multiple mechanisms. NAD+ is consumed directly of the transfer of ADP-ribose groups and synthesis of ADP-ribose polymers and cyclic ADP-ribose (cADPR). ADP-ribosylation of cellular proteins is a post-translational modification reaction involving the transfer of ADP-ribose groups from NAD+ to acceptor proteins (1). ADP-ribosylation reactions are classified as mono(ADP)-ribosylation and poly(ADP)-ribosylation depending upon the length of the transferred group (1). Moreover, these modifications differ in terms of the chemical nature of the ADP-ribosyl protein bond (i.e., cytoplasm/cell membrane versus nucleus), enzyme responsible for the formation of the linkage, and biological significance. The best characterized mono-ADP-ribosyltransferases are catalyzed by certain bacterial toxins (1) that alter critical metabolic and regulatory pathways.

The enzyme poly(ADP-ribose) polymerase (PARP), which is abundant in nuclei, is important as a regulatory enzyme (2). PARP
has been reported to be involved in cell proliferation (3), cell differentiation (1), carcinogenesis (4), and DNA repair (5). It is known that both tumor and rapidly proliferating cells have higher PARP activity levels than normal or resting cells. Recent studies have suggested that poly(ADP)-ribosylation might play a role in oral cancer and might be used as a tumor marker (6). Cyclic ADP-ribose is a potent calcium-releasing agent that may also mediate signaling pathways leading to apoptosis or necrosis (7,8). NAD$^+$ metabolism is a target for both the prevention and treatment of cancer (9). Increases in ADP-ribosylation, NAD$^+$ glycohydrolase (NADase) and ADP-ribosyl cyclase activities which are involved in the direct catabolic pathway of NAD$^+$ turnover can lead to rapid consumption of NAD$^+$ and affect the size of the NAD$^+$ pool.

In the present investigation, ADP ribosylation of tissue samples from rectal cancer patients has been evaluated as an indicator of tumor diagnosis.

**Patients and Methods**

**Tissue samples**

Fresh rectum tissues were obtained from patients with rectal cancer. After surgery, tissues were flash frozen in liquid nitrogen until use. Normal tissue was taken from the same rectum material at a site distant from the cancer tissue and evaluated for the presence of cancer cells. Only primary cancer samples were examined. The patients included in the study had not received prior radiation or chemotherapy. Frozen tissues were first ground using a mortar and pestle, and then suspended in lysis buffer containing 20 mM Tris-HCl, pH 7.0, 10% (w/w) glycerol, 10 mM MgCl$_2$, 300 units/ml DNAase I, and protease inhibitors (10 µg/ml aprotinin, 10 µg/ml leupeptin, and 2 mM PMSF). The extract obtained in this step is referred to as the crude (or total) protein extract. After centrifugation of the total extract for 30 min at 1000 g to eliminate non-lysed cells, the supernatant was used for assays (10).

**NAD$^+$ glycohydrolase and ADP-ribosyl cyclase activities**

NAD$^+$ activity in protein extracts was measured by the fluorimetric method of Muller et al. (11). The extracts were incubated in 400 µl reaction mixture containing 50 mM Tris, pH 7.4, and 200 µM 1,N$_6$-ethano-NAD$^+$. Data acquisition was started concomitantly with the addition of enzyme. Activity was measured on the basis of the initial slope of the reaction. Fluorescence measurements were performed using a Perkin-Elmer (Buckinghamshire, UK) fluorescence spectrophotometer, LS45 ($\lambda_{ex} = 310$ and $\lambda_{em} = 410$).

ADP-ribosyl cyclase activity was assayed by using NGD$^+$ as substrate and measuring the production of cyclic GDP-ribose (cGDPR) as an increase in fluorescence. cGDPR, the guanine nucleotide equivalent of cADPR, is resistant to hydrolysis (in contrast to cADPR) (12) and is also fluorescent, allowing continuous fluorimetric monitoring of the reaction. The extracts were incubated for 1 h at 37°C in 20 mM Tris-HCl, pH 7.4, containing 50 µM NGD$^+$. The excitation wavelength was set at 300 nm and the emission was measured at 410 nm with a Perkin-Elmer LS45 spectrometer. The amount of cGDPR produced was determined by comparing the fluorescence intensity with that of cGDPR standards.

**NAD$^+$ content**

NAD$^+$ concentration was determined by conversion of NAD$^+$ to NADH using the alcohol dehydrogenase reaction and assuming a molar extinction coefficient for NADH of 6.22 x 10$^6$ cm$^{-1}$ mol$^{-1}$ at 340 nm (13). Briefly, the samples were incubated at 25°C in 100 mM potassium phosphate buffer, pH 7.3, 1 mM EDTA, 5 mM DTT, and 1% (v/v) ethanol, and, after the addition of alcohol
dehydrogenase (5000 U/ml), the increase in A340 nm was monitored with a Shimadzu spectrophotometer UV-1601 (Kyoto, Japan).

**ADP-ribosylation of tissue extracts**

ADP-ribosylation was assayed as described (14). Briefly, 30-µl reaction mixtures containing 20-µl tissue sample, 10 µM (14C)-NAD and 8 mM CaCl2 were incubated for 2 h at 37ºC. After incubation, 20-µl aliquots were plated onto GF/A filters (Whatman, Houston, TX, USA), and CCl3COOH-precipitable radioactivity was determined as described (14). Thereafter, aliquots from reaction mixtures containing 50 µg protein were subjected to SDS-PAGE (15). After electrophoresis, proteins were stained with Coomassie brilliant blue, destained in 7% acetic acid and 30% methanol, dried, and exposed to Kodak X-Omat K films at -70ºC for autoradiographic analysis.

Data are reported as means ± SD. Statistical significance was assessed by the Student paired t-test. Protein concentration was determined with a Bio-Rad protein assay dye reagent kit (St. Louis, MO, USA) using bovine serum albumin as standard.

**Results and Discussion**

Figure 1 shows the extent of ADP-ribo-
sylation detected in the samples from cancer versus normal tissues. The extent of ADP-ribosylation in cancer tissue samples (mean: 95.9 ± 22.1 nmol/ml) was 8-fold higher than in normal tissue (mean: 11.4 ± 4 nmol/ml). NADase and ADP-ribosyl cyclase activities were similarly higher in cancer tissue than in control samples: 43.3 ± 9.1 vs 29.2 ± 5.2 nmol mg⁻¹ min⁻¹ NAD hydrolyzed and, correspondingly, 6.2 ± 1.6 and 1.6 ± 0.4 nmol mg⁻¹ min⁻¹ cADPR formed. NAD⁺ levels dropped from 345.5 ± 60.7 in normal tissue to 83.9 ± 36.24 µM in cancer tissue samples (Figure 1A).

When [¹⁴C]-ADP-ribosylated tissue samples were subjected to SDS-PAGE, subsequent autoradiographic analysis revealed the presence of several radiolabeled protein bands (Figure 2). The radiolabeling of a 113-kDa protein band which is considered to correspond to PARP was considerably enhanced in cancer tissue samples. Elevated NADase and ADP-ribosyl cyclase activities in cancer tissues may reflect the differences in NADase activities regarding the availability of NAD⁺ for poly(ADP)-ribosylation which may account, at least in part, for the difference in the extent of poly(ADP)-ribosylation between normal and cancer tissue. Since poly(ADP-ribose) synthesis is in the direct catabolic pathway of NAD⁺ turnover, increases in poly(ADP-ribose) synthesis can lead to rapid NAD⁺ consumption and affect the size of the NAD⁺ pool. Jacobson et al. (16) have provided evidence that the reduction in NAD⁺ for the synthesis of poly(ADP-ribose) and the synthesis of the polymer is stimulated by molecular damage to DNA. Recent studies have indicated increases in PARP activity concomitant with increased ADP-ribosylation during oral carcinogenesis (6), in human peripheral blood lymphocytes from leukemia patients and in tissue from ovarian cancer (17).

CD38 is considered to be an activation marker and also acts as a bifunctional ectoenzyme that catalyzes the conversion of NAD⁺ to cADPR and the hydrolysis of cADPR to ADPR. CD38 is expressed in activated T- and B-lymphocytes. Accordingly, elevated NADase and ADP-ribose cyclase activities may reflect a lymphocytic infiltration of tumor tissue. Indeed, Kim et al. (18) have shown that CD38 expression in uterine cervix cancers is primarily due to lymphocyte infiltration. Lymphocytic tumor infiltration indicates a host response and is generally associated with a favorable prognosis. CD38-catalyzed generation of cADPR is associated with regulation of intracellular Ca²⁺ levels and chemotaxis in neutrophils and is required for innate inflammatory immune responses (19). On the other hand, CD38 expression in leukemia may be correlated with the rate of
malignant cell proliferation, histological tumor grade, and patient survival (20). Jacobson et al. (9) showed that nicotinamide and resulting cellular NAD+ concentrations could modulate the expression of the tumor suppressor protein P53 in human breast, skin, and lung cells.

The results of the present investigation suggest that some changes occurring in NAD+ metabolism may have implications regarding tumor development and prognosis.

References